AI Article Synopsis
- The study investigates the effectiveness of docetaxel (DTX) and DTX plus ramucirumab (RAM) as second-line treatments for advanced non-small cell lung cancer (NSCLC), aiming to identify which patients are more likely to respond to these therapies.
- Out of 53 analyzed patients, only 22.6% showed a positive response to the treatments, with significant factors predicting nonresponse being lack of prior immune checkpoint inhibitors and reduction in DTX dosage after the second cycle.
- The findings indicate that maintaining DTX dosage and avoiding treatment with immune checkpoint inhibitors before administering DTX or DTX + RAM could improve response rates and overall survival in NSCLC patients.
Article Abstract
Background: Several options for second-line therapy are available for patients with advanced non-small cell lung cancer (NSCLC); however, the optimal therapy remains unclear. Docetaxel (DTX) monotherapy and DTX plus ramucirumab (RAM) are the recommended second-line treatment options. However, the efficacy of these treatments remains unsatisfactory. The aim of this study was to identify the clinical characteristics of patients with NSCLC who respond to DTX or DTX + RAM and factors that predict response.
Methods: Patients with NSCLC treated with DTX or DTX + RAM after second-line therapy were retrospectively analyzed. Patients were compared with those who responded or did not respond to the post-treatment efficacy assessment.
Results: Of 53 patients, 12 (22.6%) had lung cancer that responded to DTX or DTX + RAM therapy (response group). Multivariate analysis identified the absence of immune checkpoint inhibitors (ICIs) in the immediate prior therapy and a reduced dose of DTX after the second cycle as significant independent risk factors predicting nonresponse to DTX and DTX + RAM therapy in patients with NSCLC. The overall survival was significantly longer in the response group compared to the nonresponse group (p = 0.016).
Conclusions: Our results suggest that DTX and DTX + RAM therapies immediately after treatment with ICI-containing regimens as well as continuation of DTX without dose reduction after the second cycle may increase the response rate and prolong survival in patients with NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733157 | PMC |
| http://dx.doi.org/10.1111/1759-7714.15161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!